PCSK9 and hepatocellular carcinoma: PCSK9‐mediated LDL was positively associated with colon cancer (OR = 1.33, 95% CI: 1.10–1.16, p < 0.01) and negatively associated with rectal cancer (OR = 0.63, 95% CI: 0.53–0.76, p < 0.01) and hepatocellular carcinoma (OR = 0.63, 95% CI: 0.40–0.97, p = 0.04).